2nd Quarter - Report

NCHC ACTION FUND for NCHC ACTION FUND

Period 2nd Quarter 2017 Filed Aug 2, 2017 Signed by Larry McNeely

Official filing
Firm
NCHC ACTION FUND
Client
NCHC ACTION FUND
Income
—
Expenses
$30,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Prescription Drug Pricing

LobbyistCovered position, as disclosed
JOHN ROTHER —

Contacted: Health & Human Services, Dept of (HHS); SENATE; HOUSE OF REPRESENTATIVES

Pharmacy PHA

Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017

LobbyistCovered position, as disclosed
JOHN ROTHER —

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: S. 974 (115th), H.R. 2430 (115th), H.R. 2439 (115th), H.R. 2051 (115th), S. 1131 (115th), S. 934 (115th)

Health Issues HCR

Prescription drug pricing. S. 974 - CREATES Act. S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017 H.R. 2051 - FAST Generics Act of 2017

LobbyistCovered position, as disclosed
JOHN ROTHER —

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: S. 934 (115th), H.R. 2430 (115th), S. 974 (115th), S. 1131 (115th), H.R. 2439 (115th), H.R. 2051 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.